MaxCyte Overview
MaxCyte (MXCT) has a ROE of -22.45%, below the Materials sector average of 19.67%.
Get informed when a big investor buys or sells
+ Follow-22.45%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for MXCT is -22.45%. That is below the Materials sector average of 19.67%. Investors often review this figure alongside MaxCyte's historical trend and sector peers before judging valuation or financial health.
Against Materials companies, MXCT currently prints -22.45% for ROE, while the sector average sits near 19.67%. That is roughly 214.1% below the sector mean. Large gaps often invite a closer look at MaxCyte's growth, margins, and balance sheet.
Return on Equity shows how effectively MaxCyte converts resources into returns. At -22.45%, MXCT may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting MXCT's ROE (-22.45%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack MaxCyte's ROE against similar Materials names. You can also browse sector and industry screens on Stockcircle for a broader set of Materials companies and their key multiples and fundamentals.
